BeyondSpring Files 2021 Annual Report on Form 20-F
BeyondSpring Inc. (Nasdaq: BYSI) has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021, with the SEC. The report includes audited consolidated financial statements, which investors can access on the SEC's website or BeyondSpring’s site under the Investors section. The company is focused on developing innovative cancer therapies, including its lead asset, Plinabulin, which has shown promising Phase 3 results in extending overall survival for certain lung cancer patients. A hard copy of the annual report is available for shareholders upon request.
- Plinabulin demonstrated positive Phase 3 results in extending overall survival for NSCLC patients.
- The combination of Plinabulin and G-CSF has shown potential to prevent chemotherapy-induced neutropenia.
- BeyondSpring’s pipeline includes additional promising immuno-oncology assets.
- None.
NEW YORK, April 14, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission (“SEC”) on April 14, 2022. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at www.sec.gov and on the Company’s website at www.beyondspringpharma.com under “Financials & Filings” in the Investors section.
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 28 Liberty Street, 39th Floor, New York, NY 10005 USA.
About BeyondSpring
Headquartered in New York City, BeyondSpring is a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class lead asset, Plinabulin, is being developed as a “pipeline in a drug” in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). The Plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data. In the DUBLIN-3 study, a global, randomized, active controlled Phase 3 study, the Plinabulin and docetaxel combination has met the primary endpoint of extending overall survival compared to docetaxel alone, in 2nd/3rd line NSCLC (EGFR wild type). Additionally, Plinabulin is being broadly studied in combination with various immuno-oncology regimens that could boost the efficacy of PD-1/PD-L1 antibodies in seven different cancers. In addition to Plinabulin, BeyondSpring’s pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.
Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
arr@lifesciadvisors.com
FAQ
What are the highlights from BeyondSpring's annual report for 2021?
How can investors access BeyondSpring's annual report?
What is the significance of Plinabulin in BeyondSpring's pipeline?
Is a hard copy of the annual report available to shareholders?
What is BeyondSpring's focus as a biopharmaceutical company?
